论文部分内容阅读
目的评价国产氯吡格雷(泰嘉)和进口氯吡格雷(波立维)对经皮冠状动脉介入治疗(PCI)术后抗血小板治疗的长期疗效及成本。方法将接受冠状动脉支架植入术的118例冠心病患者随机分为泰嘉组(n=60)和波立维组(n=58)。2组均于支架植入术后口服氯吡格雷每日75mg,共服用12个月(药物涂层支架DES)。评价术后12个月主要心血管不良事件及主要不良反应。结果 12个月随访期内,2组患者主要心血管不良事件、主要不良反应差异无统计学意义(P>0.05)。泰嘉组成本4380元,波立维组成本7555.5元。结论国产与进口氯吡格雷临床疗效及安全性相当,国产氯吡格雷经济便宜,值得临床推广。
Objective To evaluate the long-term efficacy and cost of antiplatelet therapy after percutaneous coronary intervention (PCI) by domestic clopidogrel and imported clopidogrel. Methods A total of 118 patients with coronary heart disease undergoing coronary stent implantation were randomly divided into two groups: Taijia group (n = 60) and Bolivian group (n = 58). Both groups received oral clopidogrel 75 mg daily after stent implantation for a total of 12 months (drug-eluting stent DES). The major adverse cardiovascular events and major adverse events at 12 months postoperatively were evaluated. Results During the 12-month follow-up period, there was no significant difference in major adverse cardiovascular events and major adverse reactions between the two groups (P> 0.05). Taijia group cost 4380 yuan, wave Liwei group cost 7555.5 yuan. Conclusion The clinical efficacy and safety of domestic and imported clopidogrel are quite similar. The domestic clopidogrel is cheap and is worthy of clinical promotion.